Latest Galderma Stories
Skin care industry veteran Anne M. Egger brings 30 years of experience to TopMD, Inc.'s Board of Directors. Dallas, TX (PRWEB) May 13, 2013 Dallas-based TopMD™ Skin Care, makers of CLn® BodyWash and CLn® SportWash, today announced its vice president of marketing and sales, Anne Egger, will join TopMD, Inc. Board of Directors. Egger is a dermatology industry expert of 30 years. She has served as TopMD’s vice president of marketing and sales since 2012, leading the...
SCHAUMBURG, Ill. and SOPHIA ANTIPOLIS, FRANCE, April 25, 2013 /PRNewswire/ -- The American Academy of Dermatology (Academy), in partnership with Galderma Research & Development, SNC is pleased to announce the creation of the American Academy of Dermatology Translational Biotechnology Fellowship. The new fellowship will offer a dermatologist the opportunity to work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis,...
MISSISSAUGA, ON, April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been...
MISSISSAUGA, ON, March 27, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012. Fourth Quarter and Recent Corporate Developments: -- Received confirmation from the Company's...
BASKING RIDGE, N.J., March 21, 2013 /PRNewswire/ -- Galderma, a leading global pharmaceutical company focused on dermatology, wanted a cost-efficient means of increasing the capacity of its IT global network infrastructure to support its increasingly data-intensive workload. The company chose a fully managed communications network from Verizon Enterprise Solutions, underpinned by Verizon's comprehensive security solutions and professional service expertise. The result is a secure,...
Multi-Media Program Provides Epiduo(®) Gel Patients with Tools to Track Treatment FORT WORTH, Texas, March 11, 2013 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the availability of the Epiduo(®) TAP (Treatment, Adherence, and Performance) Program, a first-of-its-kind online and mobile patient platform, powered by HealthPrize, that educates acne patients about the proper application of Epiduo(®) (adapalene and benzoyl peroxide 0.1%/2.5%) Gel and encourages acne...
MISSISSAUGA, ON, March 11, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in...
NEW YORK, Feb. 26, 2013 /PRNewswire/ -- Educational Testing and Assessment Systems (ETAS), the creators of the most comprehensive exam prep resource in dermatology, has developed and launched an upgraded version of the Dermatology In-Review app. The app, entitled Kodachrome Flashcard Series, allows users to customize flashcard sets, and to quickly and easily scroll through hundreds of exam-relevant images and answers. Dermatology In-Review is one of the most popular Board exam prep...
FORT WORTH, Texas, Feb. 19, 2013 /PRNewswire/ -- Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Epiduo(® )(adapalene 0.1%/BPO 2.5%) Gel to treat acne in children as young as 9 years old based on the results of a recent clinical study in pediatric patients. Epiduo(® )Gel had been previously approved for patients 12 years of age and older. "Pediatricians and dermatologists are seeing a steady increase in children reaching...
FORT WORTH, Texas, Feb. 12, 2013 /PRNewswire/ -- Galderma Laboratories, L.P.'s Tri-Luma(® )(fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now available to the more than 7 million people who suffer from this chronic skin condition. Tri-Luma(® )Cream contains a clinically-proven formula which...
